From 2001 to the present, as the Founder and Managing Director of Virchow Biotech Pvt Ltd, I have driven the company’s growth into a globally recognized biopharma leader, backed by over 24 years of operational experience. Our diverse product range includes bio generic and recombinant therapeutics, such as Recombinant Platelet-Derived Growth Factor (rhPDGF) for wound healing, Recombinant Parathyroid Hormone (PTH) for osteoporosis, Pegylated Interferon, and Rasburicase. In addition, we offer specialized products for oncology, cardiology, neurology, immunology, and anti-venom treatments for snake bites and rabies. Headquartered in Hyderabad with offices in the USA, VBPL’s USFDA, ISO 13485:2016, and WHO-GMP certifications reflect our unwavering commitment to healthcare quality and safety. Supported by an innovative R&D team and dedicated manufacturing workforce, VBPL has pioneered the commercialization of several bio generics,     advancing therapeutic solutions for patients worldwide.

Beyond our own products, we provide Contract Research and Manufacturing Services and partner globally for co-development initiatives. With strict adherence to cGMP standards and facilities accredited by global regulatory bodies, VBPL has built a solid, appreciative customer base across international and domestic markets. Today, we proudly employ over 2,000 professionals across multiple production facilities, supplying our products to 76 countries and establishing a strong global footprint. To further this reach, we are expanding with new facilities in Colombia and Kenya, supplementing our recent U.S. market establishment and positioning us to deliver high-quality, affordable biopharmaceuticals to an even broader global audience.